We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed at $52.61 in the latest trading session, marking a +0.04% move from the prior day. This change outpaced the S&P 500's 0.76% loss on the day. Elsewhere, the Dow lost 0.82%, while the tech-heavy Nasdaq lost 0.9%.
Coming into today, shares of the biopharmaceutical company had lost 9.06% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.41%.
BMY will be looking to display strength as it nears its next earnings release, which is expected to be February 4, 2019. In that report, analysts expect BMY to post earnings of $0.84 per share. This would mark year-over-year growth of 23.53%. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.84 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +27.57% and +8.68%, respectively.
Investors should also note any recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.54% higher within the past month. BMY currently has a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 13.69 right now. For comparison, its industry has an average Forward P/E of 14.52, which means BMY is trading at a discount to the group.
Investors should also note that BMY has a PEG ratio of 1.48 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed at $52.61 in the latest trading session, marking a +0.04% move from the prior day. This change outpaced the S&P 500's 0.76% loss on the day. Elsewhere, the Dow lost 0.82%, while the tech-heavy Nasdaq lost 0.9%.
Coming into today, shares of the biopharmaceutical company had lost 9.06% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.41%.
BMY will be looking to display strength as it nears its next earnings release, which is expected to be February 4, 2019. In that report, analysts expect BMY to post earnings of $0.84 per share. This would mark year-over-year growth of 23.53%. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.84 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +27.57% and +8.68%, respectively.
Investors should also note any recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.54% higher within the past month. BMY currently has a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 13.69 right now. For comparison, its industry has an average Forward P/E of 14.52, which means BMY is trading at a discount to the group.
Investors should also note that BMY has a PEG ratio of 1.48 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.